Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 471

1.

Inhibitors of Plasmodium falciparum methionine aminopeptidase 1b possess antimalarial activity.

Chen X, Chong CR, Shi L, Yoshimoto T, Sullivan DJ Jr, Liu JO.

Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14548-53. Epub 2006 Sep 18.

2.

Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo.

Chen X, Xie S, Bhat S, Kumar N, Shapiro TA, Liu JO.

Chem Biol. 2009 Feb 27;16(2):193-202. doi: 10.1016/j.chembiol.2009.01.006.

3.

The M18 aspartyl aminopeptidase of the human malaria parasite Plasmodium falciparum.

Teuscher F, Lowther J, Skinner-Adams TS, Spielmann T, Dixon MW, Stack CM, Donnelly S, Mucha A, Kafarski P, Vassiliou S, Gardiner DL, Dalton JP, Trenholme KR.

J Biol Chem. 2007 Oct 19;282(42):30817-26. Epub 2007 Aug 20.

4.

Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the antimalarial activity of bestatin.

Gardiner DL, Trenholme KR, Skinner-Adams TS, Stack CM, Dalton JP.

J Biol Chem. 2006 Jan 20;281(3):1741-5. Epub 2005 Nov 14.

5.

Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy.

Reungprapavut S, Krungkrai SR, Krungkrai J.

J Enzyme Inhib Med Chem. 2004 Jun;19(3):249-56.

PMID:
15499996
6.

Why is the Plasmodium falciparum hexose transporter a promising new drug target?

Joët T, Morin C, Fischbarg J, Louw AI, Eckstein-Ludwig U, Woodrow C, Krishna S.

Expert Opin Ther Targets. 2003 Oct;7(5):593-602. Review.

PMID:
14498822
7.

Recombinant Plasmodium falciparum dihydrofolate reductase-based in vitro screen for antifolate antimalarials.

Brobey RK, Sano G, Itoh F, Aso K, Kimura M, Mitamura T, Horii T.

Mol Biochem Parasitol. 1996 Oct 30;81(2):225-37.

PMID:
8898337
8.

Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.

Skinner-Adams TS, Lowther J, Teuscher F, Stack CM, Grembecka J, Mucha A, Kafarski P, Trenholme KR, Dalton JP, Gardiner DL.

J Med Chem. 2007 Nov 29;50(24):6024-31. Epub 2007 Oct 26.

PMID:
17960925
9.

Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.

Gardiner DL, Skinner-Adams TS, Brown CL, Andrews KT, Stack CM, McCarthy JS, Dalton JP, Trenholme KR.

Expert Rev Anti Infect Ther. 2009 Nov;7(9):1087-98. doi: 10.1586/eri.09.93. Review.

PMID:
19883329
10.

Aminopeptidases of malaria parasites: new targets for chemotherapy.

Trenholme KR, Brown CL, Skinner-Adams TS, Stack C, Lowther J, To J, Robinson MW, Donnelly SM, Dalton JP, Gardiner DL.

Infect Disord Drug Targets. 2010 Jun;10(3):217-25. Review.

PMID:
20334618
11.

Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors.

Flipo M, Florent I, Grellier P, Sergheraert C, Deprez-Poulain R.

Bioorg Med Chem Lett. 2003 Aug 18;13(16):2659-62.

PMID:
12873488
12.

A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline.

Davioud-Charvet E, Delarue S, Biot C, Schwöbel B, Boehme CC, Müssigbrodt A, Maes L, Sergheraert C, Grellier P, Schirmer RH, Becker K.

J Med Chem. 2001 Nov 22;44(24):4268-76.

PMID:
11708927
13.

Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum.

Friebolin W, Jannack B, Wenzel N, Furrer J, Oeser T, Sanchez CP, Lanzer M, Yardley V, Becker K, Davioud-Charvet E.

J Med Chem. 2008 Mar 13;51(5):1260-77. doi: 10.1021/jm7009292. Epub 2008 Feb 9.

PMID:
18260613
14.

The impact of whole genome sequence data on drug discovery--a malaria case study.

Joachimiak MP, Chang C, Rosenthal PJ, Cohen FE.

Mol Med. 2001 Oct;7(10):698-710.

15.

Synthesis and antimalarial activity in vitro of potential metabolites of ferrochloroquine and related compounds.

Biot C, Delhaes L, N'Diaye CM, Maciejewski LA, Camus D, Dive D, Brocard JS.

Bioorg Med Chem. 1999 Dec;7(12):2843-7.

PMID:
10658588
16.

Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.

Cunningham E, Drag M, Kafarski P, Bell A.

Antimicrob Agents Chemother. 2008 Sep;52(9):3221-8. doi: 10.1128/AAC.01327-07. Epub 2008 May 5.

17.

Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents.

Flipo M, Beghyn T, Leroux V, Florent I, Deprez BP, Deprez-Poulain RF.

J Med Chem. 2007 Mar 22;50(6):1322-34. Epub 2007 Feb 28.

PMID:
17326615
18.

The alpha-carbonic anhydrase from the malaria parasite and its inhibition.

Krungkrai J, Supuran CT.

Curr Pharm Des. 2008;14(7):631-40. Review.

PMID:
18336308
19.

A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90.

Shahinas D, Liang M, Datti A, Pillai DR.

J Med Chem. 2010 May 13;53(9):3552-7. doi: 10.1021/jm901796s.

PMID:
20349996
20.

Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.

Carroll CD, Patel H, Johnson TO, Guo T, Orlowski M, He ZM, Cavallaro CL, Guo J, Oksman A, Gluzman IY, Connelly J, Chelsky D, Goldberg DE, Dolle RE.

Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20.

PMID:
9873534

Supplemental Content

Support Center